This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck
The Zacks Analyst Blog Highlights: Eli Lilly, Charter, Eaton, Autodesk and Cypress Semiconductor
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Charter, Eaton, Autodesk and Cypress Semiconductor
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates
by Kinjel Shah
J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.
LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day
by Zacks Equity Research
LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day
Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis
by Zacks Equity Research
Lilly (LLY) enjoys strong fundamentals, which can help it withstand the short-term impact of the pandemic.
Bull of the Day: Eli Lilly (LLY)
by Tracey Ryniec
This drug maker is expected to grow earnings by the double digits in 2020.
Top Analyst Reports for Eli Lilly, Charter Communications & Eaton
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), Charter Communications (CHTR) and Eaton (ETN).
Pharma Giant Eli Lilly (LLY) Stock is a Buy During the Coronavirus Economy
by Benjamin Rains
Eli Lilly (LLY) stock closed the first quarter above where it started, which was no easy task. So let's dive into why investors might want to buy LLY stock right now...
Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA
by Zacks Equity Research
Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.
Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
3 Drugmakers Still Worth Betting on Amid Coronavirus Woes
by Indrajit Bandyopadhyay
Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.
Buy this High-Yield Large Cap Pharma Stock for Income Amid Coronavirus
by Benjamin Rains
AbbVie (ABBV) stock popped on Tuesday. This is part of the global pharmaceutical giant's larger 20% surge in the last week as the market tries to mount a comeback amid the coronavirus uncertainty...
Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children
by Zacks Equity Research
The FDA approves Eli Lilly's (LLY) sBLA for Taltz injection to treat pediatric patients with moderate to severe plaque psoriasis. Stock up.
Vertex to Halt Enrollment Due to Coronavirus, Keeps Sales View
by Zacks Equity Research
Vertex (VRTX) announces plan to halt enrollment and delay study initiation amid coronavirus pandemic. However, it does not expect any supply chain disruption and maintains its business outlook for 2020.
AVEO Stops AML Study on Ficlatuzumab Amid Coronavirus Pandemic
by Zacks Equity Research
AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia to combat the COVID-19 outbreak.
Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia
by Zacks Equity Research
The FDA approves Bristol Myers' (BMY) Zeposia for the treatment of adults with relapsing forms of multiple sclerosis.
Pharma, Biotech Players Step Up Efforts Against Coronavirus
by Indrajit Bandyopadhyay
Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.
Pfizer's Eczema Drug Eucrisa Gets FDA Approval for Infants
by Zacks Equity Research
Pfizer (PFE) gets FDA approval for label expansion of Eucrisa to include children aged three months to two years with mild-to-moderate atopic dermatitis or eczema.
Agios' IND for PKR Activator AG-946 Gets FDA Clearance
by Zacks Equity Research
The FDA passes Agios' (AGIO) investigational new drug application for its next-generation PKR activator, AG-946. The company plans to begin a phase I study on the same in mid-2020.
Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure
by Kinjel Shah
Supply-chain disruptions due to coronavirus outbreak may hurt biotech companies' first-quarter earnings. However, those making treatments/vaccines may make huge profits if their products get approval.
Lilly Gets CRL for Jardiance in Type I Diabetes Indication
by Zacks Equity Research
Lilly's (LLY) label expansion application seeking approval of its type II diabetes medicine as a treatment for type I diabetes fails to get approval from the FDA.
The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck
Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates
by Kinjel Shah
Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.
Pfizer's Eczema Drug & Pneumococcal Vaccine Succeed in Study
by Zacks Equity Research
Pfizer's (PFE) atopic dermatitis (eczema) candidate, abrocitinib, and pneumococcal conjugate vaccine candidate meet primary endpoints in their respective late-stage studies.